COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00235521
Recruitment Status : Completed
First Posted : October 10, 2005
Last Update Posted : December 12, 2012
Information provided by (Responsible Party):
Matthias Gorenflo, Heidelberg University

Brief Summary:
Inhaled nitrous oxide (iNO) will be compared to aerosolized iloprost (ILO) in pediatric patients after cardiac surgery with pulmonary hypertension. The hypothesis is that iloprost is more effective in preventing pulmonary hypertensive crises.

Condition or disease Intervention/treatment Phase
Pulmonary Hypertension Drug: aerosolized iloprost Not Applicable

Detailed Description:

Investigators, Study Sites: Single-center trial at the Department of Pediatric Cardiology, Department of Cardiac Surgery and Department of Anesthesiology, University Medical Center, Heidelberg, Germany Exploratory proof of concept study (Investigator initiated trial)

Indication: Postoperative pulmonary hypertension in infants and children undergoing cardiopulmonary bypass surgery for intracardiac repair of left-to-right shunt

Objectives: To compare the efficacy of aerosolized iloprost with inhaled nitric oxide to prevent postoperative pulmonary hypertensive crises

Design: Exploratory, open label, randomized study with parallel-group design;

Duration of observation: 72 hours

Population: Infants older than 4 weeks and children less than 18 months of age presenting with left-to-right shunt and increased pulmonary blood flow. Inclusion will be independent on the presence or absence of preoperative pulmonary hypertension

Sample Size:

  • 20 patients: inhaled nitric oxide (iNO) - group;
  • 20 patients: aerosolized iloprost (ILO) -group


  • Both groups: controlled ventilation, sedation, analgetics, inotropic substances as required, standardized intensive care treatment.
  • iNO - group: concentration of iNO at 10 ppm; administered by mechanical ventilation.
  • ILO - group: aerosolized Iloprost at a dose of 0,5 µg/kg body weight (12x / 24h), administered by ultrasound nebulizer.

Efficacy Parameters: Occurrence of "minor" or "major" pulmonary hypertensive crises (PHTC)

Safety Parameters: Arterial blood pressure, oxygen saturation, complete blood count

Statistical Procedures: All analyses in this exploratory trial are descriptive, giving confidence intervals for differences between treatment groups.

Primary analysis variable: Rate of occurrence of "major" or "minor" pulmonary hypertensive crises

Secondary variables: Presence of hours of pulmonary hypertension, Duration of mechanical ventilation

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Inhaled Nitric Oxide With Aerosolized Iloprost (Ventavis®) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery
Study Start Date : May 2005
Actual Primary Completion Date : October 2008
Actual Study Completion Date : October 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Iloprost

Primary Outcome Measures :
  1. Number of pulmonary hypertensive crises (major and/or minor)

Secondary Outcome Measures :
  1. Treatment with aerosolized ILO is equally effective as iNO in reducing the pulmonary artery pressure (PAP) within the first 72 hours after cardiopulmonary bypass surgery (CPB)
  2. Patients treated with aerosolized ILO can be weaned earlier from mechanical ventilation than patients on iNO treatment
  3. Patients treated with aerosolized ILO show the same in-hospital mortality as patients treated with iNO

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 2 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Informed consent by parents or legal representatives
  • Age: Infants older than 4 weeks of age and children less than 1½ years of age.
  • Presence of a left-to-right shunt with increased pulmonary blood flow. The specific defects that will be present are:

    • Aortopulmonary (AP) - Window
    • Atrioventricular septal defect (AVSD)
    • Double outlet right ventricle (DORV)
    • Total anomalous pulmonary venous drainage (TAPVD)
    • Truncus arteriosus
    • Ventricular septal defect (VSD)
  • Presence of postoperative PH immediately after intracardiac repair:

    • Patients will be enrolled if mean PAP after intracardiac repair exceeds 25 mmHg after weaning from CPB.

Exclusion Criteria:

  • Specific cardiac defects:

    • Atrial septal defect (ASD)
    • Cyanotic congenital heart disease
    • Univentricular atrio-ventricular - connexion
    • Valvular or subvalvular pulmonary or aortic stenosis
  • Specific circumstances:

    • Emergency cardiac surgery
    • Children presenting with infection after cardiac surgery
    • Infants on extracorporeal membrane oxygenation (ECMO) before cardiac surgery
    • Infants/children treated with epoprostenol
  • Concomitant diseases:

    • Systemic arterial hypertension
    • Renal failure
    • Diabetes mellitus
    • Known bleeding disorders (known disorders of blood coagulation and hemostasis)
    • Infection during the first 24 hours after cardiac surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00235521

Layout table for location information
University of Heidelberg, Medical Faculty, Department of Pediatric Cardiology
Heidelberg, Germany, 69120
Sponsors and Collaborators
Heidelberg University
Layout table for investigator information
Principal Investigator: Matthias Gorenflo, MD, PhD Heidelberg University
Layout table for additonal information
Responsible Party: Matthias Gorenflo, Prof. Dr. med., Heidelberg University Identifier: NCT00235521    
Other Study ID Numbers: Iloprost-Study
First Posted: October 10, 2005    Key Record Dates
Last Update Posted: December 12, 2012
Last Verified: December 2012
Keywords provided by Matthias Gorenflo, Heidelberg University:
Pulmonary hypertension
Cardiac Surgery
Pediatric Patients
nitric oxide
Pulmonary hypertension after cardiac surgery in pediatric patients, 0 - 2 years old
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Platelet Aggregation Inhibitors
Vasodilator Agents